insulin human winthrop
sanofi-aventis deutschland gmbh - insulin human - Šećerna bolest - lijekovi koji se koriste u dijabetesu - diabetes mellitus gdje je potrebno liječenje inzulinom. inzulin ljudske winthrop rapid je pogodan za liječenje hiperglikemijsku komu i ketoacidoza, kao i za postizanje unaprijed, intra - i postoperativna stabilizacija u bolesnika sa šećernom bolešću.
lasix 40 mg tablete
sanofi winthrop industrie, 6 boulevard de l'europe, quetigny, francuska - furosemid - tableta - 40 mg - urbroj: jedna tableta sadrži 40 mg furosemida
eloxatin 5 mg/1 ml koncentrat za rastvor za infuziju
amicus pharma d.o.o. - oksaliplatin - koncentrat za rastvor za infuziju - 5 mg/1 ml - 1 ml koncentrata za rastvor za infuziju sadrži: 5 mg oksaliplatina
eloxatin 5 mg/1 ml koncentrat za rastvor za infuziju
amicus pharma d.o.o. - oksaliplatin - koncentrat za rastvor za infuziju - 5 mg/1 ml - 1 ml koncentrata za rastvor za infuziju sadrži: 5 mg oksaliplatina
amphotericin b bharat 50 mg/1 bočica prašak za rastvor za infuziju
rhei life d.o.o. bijeljina - amfotericin b - prašak za rastvor za infuziju - 50 mg/1 bočica - 1 bočica sadrži: 50 mg lipozomalnog amfotericina b
zaltrap
sanofi winthrop industrie - aflibercept - kolorektalne neoplazme - antineoplastična sredstva - liječenje metastaziranog kolorektalnog karcinoma (mcrc).
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenti za dermatitis, isključujući kortikosteroide - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
lantus 3.6378 mg/1 ml rastvor za injekciju u patroni
amicus pharma d.o.o. - гларгин inzulin - rastvor za injekciju u patroni - 3.6378 mg/1 ml - 1 ml rastvora za injekciju u patroni sadrži: 100 jedinica (3,6378 mg) insulin glargin
lantus 100 jedinica/1 ml rastvor za injekciju u napunjenom penu
sanofi d.o.o. - гларгин inzulin - rastvor za injekciju u napunjenom penu - 100 jedinica/1 ml - 1 ml rastvora za injekciju sadrži: 100 jedinica (3,64 mg) insulina glargin
zaltrap 25 mg/1 ml koncentrat za rastvor za infuziju
amicus pharma d.o.o. - aflibercept - koncentrat za rastvor za infuziju - 25 mg/1 ml - 8 ml koncentrata za rastvor za infuziju sadrži: 200 mg aflibercepta